Contact Us marketing@medicilon.com
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
SERVICES
SERVICES
01 Drug Discovery
Chemistry Research Biology Research Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates Active Pharmaceutical Ingredients Pharmaceutical preparation Analytical Method Development and Quality Control CMC Filings Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics Drug Safety Evaluation DMPK Bioanalysis IND Filings
PLATFORM
PLATFORM
01 One-stop Integrated Services
Liposome Drug Development Drug Discovery Pharmaceutical Research Preclinical Research Botanical Drug Preclinical R&D
02 Innovative Drug R&D Services
Peptide Drug Conjugate (PDC) Antibody Nucleic Acid Drug Cellular Immunotherapies mRNA Vaccine PROTAC ADC
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection Metabolite Identification (MetID) Drug Forming Research Flow Cytometry Technology SEND Format Conversion Flow Sorting NanoString nCounter Detection Routes of Drug Administration
04 Drug Efficacy Evaluation for Common Diseases
Rodent Cerebrovascular Disease Inflammatory and Immune Diseases IO Pharmacodynamic Model
05 High-end Preparations Technology Platform
Skin Topical Preparation Ophthalmic drug Inhalation drug
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service KRAS-targeted Drugs R&D Service GLP-1 New Drug R&D Service
07 Safety Assessment Lab of Process Chemistry

08 Public Services
CAREERS
Talent Development
Campus Recruitment
Recruitment
NEWS
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
INVESTORS
Stock Information
Investment Contact
CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
CN
×
中
Close Button
News and Events
Medicilon Events Featured Stories Market Events Videos A.C.E.
HomenewsFeatured Stories

Featured Stories

Hot information：
Top 10 Global CDMO Enterprises| The Meaning of IND, NDA and ANDA| Top 10 Global Clinical Research Organizations in 2021
Sep 06,2022
The ADC drug industry is thriving!
Medicilon has rich experience in developing and validating analysis methods for different targets, and can effectively analyze the expression level and accessibility of targets according to needs, and provide constructive suggestions for target selection.
More
The ADC drug industry is thriving!
Sep 02,2022
ALK inhibitors: iterative upgrade, targeted therapies strike with precision
Fourth-generation ALK inhibitors are currently under investigation. Biomedical technology is constantly advancing and drug development is constantly evolving. Medicilon has established a one-stop platform for preclinical biopharmaceutical R&D services, including drug discovery, pharmacological research, and preclinical research.
More
ALK inhibitors: iterative upgrade, targeted therapies strike with precision
Aug 30,2022
ADC drug interpretation (4) | ADC market situation and competitive landscape
In recent years, the global ADC drug R&D and investment has been escalating. With the advancement of technology, ADC has not only broken through the classic antibody + linker + small molecule toxin model in structure, but also become a new type of ADC drugs.
More
ADC drug interpretation (4) | ADC market situation and competitive landscape
Aug 29,2022
Interpretation of ADC drugs (3) | An article to analyze the difficulties of ADC drug development
The complex and diverse structure of ADC drugs, as well as the complexities of in vivo actions and metabolic processes, bring multiple challenges to CMC research and preclinical research.
More
Interpretation of ADC drugs (3) | An article to analyze the difficulties of ADC drug development
Aug 26,2022
What is the subtleties of Antibody-drug conjugates
Antibody-drug conjugates (ADCs) have been the focus of tumor therapy research in recent years. The mechanism of action of ADC is complex and usually requires drug internalization followed by intracellular processing and payload release.
More
What is the subtleties of Antibody-drug conjugates
Aug 01,2022
ADC, precision and deep cultivation for targeted drug delivery
Antibody conjugate (ADC) is the focus of tumor therapy research in recent years. Because of its good targeting and obvious clinical efficacy, ADC has become the frontier of antibody drug research and development and is one of the strategic focuses of new drug research and development in China.
More
ADC, precision and deep cultivation for targeted drug delivery
Aug 01,2022
CGeneTech's Class 1 innovative drug CGT-9475 has achieved dual application and approval in China and the US with the help of Medicilon's one-stop preclinical pharmaceutical R&D service platform
On July 22, CGT-9475, a new generation of ALK inhibitor independently developed by CGeneTech (Suzhou, China) Co., Ltd. (CGeneTech), was approved by the US Food and Drug Administration (FDA) to enter the clinical trial.
More
CGeneTech's Class 1 innovative drug CGT-9475 has achieved dual application and approval in China and the US with the help of Medicilon's one-stop preclinical pharmaceutical R&D service platform
Jun 10,2022
Empowering nucleic acid drug therapy to meet the third wave of new drug research and development
The global epidemic of COVID-19 has made mRNA vaccines a great success in the market, promoted the research and development of nucleic acid drugs and the development and maturity of technical platforms, and demonstrated its potential and energy to the global pharmaceutical industry, becoming part of the third biotechnology revolution.
More
Empowering nucleic acid drug therapy to meet the third wave of new drug research and development
May 30,2022
Accurate model, holding the key to unlocking the treatment of autoimmune diseases
We have constructed a variety of mature animal models of autoimmune diseases, which can comprehensively reflect and evaluate the pathological and pharmacodynamic characteristics of various diseases, especially experienced of the pharmacodynamic evaluation ofcurrent popular JAKs inhibitors.
More
Accurate model, holding the key to unlocking the treatment of autoimmune diseases
May 07,2022
New Drug Discovery and Development
Drug Discovery Period >> Drug Development and Registration Period >> Drug Release to Market Drug Marketing and Product Line Expansion
More
New Drug Discovery and Development
Stock Code
688202

Global

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(781)535-1428(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->